Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy

NCT00437073 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00437073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00437073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2007
Completion date
February 28, 2010
Enrollment
22 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast